MA55504A - Anticorps dirigés contre le liraglutide et leur utilisation - Google Patents
Anticorps dirigés contre le liraglutide et leur utilisationInfo
- Publication number
- MA55504A MA55504A MA055504A MA55504A MA55504A MA 55504 A MA55504 A MA 55504A MA 055504 A MA055504 A MA 055504A MA 55504 A MA55504 A MA 55504A MA 55504 A MA55504 A MA 55504A
- Authority
- MA
- Morocco
- Prior art keywords
- liraglutide
- antibodies against
- antibodies
- against liraglutide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962827444P | 2019-04-01 | 2019-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA55504A true MA55504A (fr) | 2022-02-09 |
Family
ID=70154403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA055504A MA55504A (fr) | 2019-04-01 | 2020-03-31 | Anticorps dirigés contre le liraglutide et leur utilisation |
Country Status (6)
Country | Link |
---|---|
US (2) | US11208477B2 (fr) |
EP (1) | EP3947451A1 (fr) |
JP (1) | JP2022527812A (fr) |
CN (1) | CN113677702A (fr) |
MA (1) | MA55504A (fr) |
WO (1) | WO2020201280A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022140413A1 (fr) * | 2020-12-22 | 2022-06-30 | The Regents Of The University Of Michigan | Anticorps spécifiques de l'amyloïde et utilisations associées |
CN116425858B (zh) * | 2023-03-01 | 2024-04-19 | 浙江大学 | 一种荧光修饰的司美格鲁肽衍生物及其制备方法与应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5620850A (en) | 1994-09-26 | 1997-04-15 | President And Fellows Of Harvard College | Molecular recognition at surfaces derivatized with self-assembled monolayers |
AU5685296A (en) | 1995-05-17 | 1996-11-29 | Novo Nordisk A/S | Immunoassay for glucagon like protein 1 (glp-1) in plasma |
CA2468374C (fr) | 1996-08-30 | 2010-12-21 | Novo-Nordisk A/S | Derives de glp-1 |
JP4187277B2 (ja) | 1997-04-30 | 2008-11-26 | エンゾン ファーマシューティカルズ, インコーポレイテッド | グリコシル化し得る抗原結合単鎖タンパク質、それらの生成および使用 |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2005040219A1 (fr) | 2003-10-28 | 2005-05-06 | Novo Nordisk A/S | Peptides fixant la laminine-5 gamma-2, compositions associees et leurs applications |
BRPI0516011A (pt) | 2004-09-24 | 2008-08-19 | Amgen Inc | moléculas fc modificadas |
TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
CA2634784A1 (fr) | 2005-12-22 | 2007-07-05 | Centocor, Inc. | Corps mimetiques humains glp-1 et compositions pour traiter l'obesite et les troubles associes, procedes et utilisations |
EP2288918A1 (fr) | 2008-05-23 | 2011-03-02 | Amylin Pharmaceuticals, Inc. | Biodosages de l'agoniste du récepteur du glp-1 |
MX347291B (es) | 2009-03-20 | 2017-04-17 | Amgen Inc | Inmunoglobulinas portadoras y usos de las mismas. |
EP2666021A1 (fr) | 2011-01-21 | 2013-11-27 | IR2DX, Inc. | Biomarqueurs pour détermination rapide de l'efficacité d'un médicament |
WO2014056199A1 (fr) | 2012-10-12 | 2014-04-17 | 清华大学 | Procédés de production et de purification d'un polypeptide |
EP3068891A1 (fr) | 2013-11-13 | 2016-09-21 | Aequus Biopharma Inc. | Glycoprotéines modifiées et leurs utilisations |
AR098615A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
CN103884846B (zh) | 2014-03-06 | 2016-06-08 | 杭州九源基因工程有限公司 | 一种利拉鲁肽生物学活性的检测方法 |
CN104267194B (zh) | 2014-09-23 | 2016-01-13 | 上海市东方医院 | 人胰高血糖素样肽-1、抗体及其试剂盒 |
GR20140100479A (el) * | 2014-09-23 | 2016-05-05 | Novetide, Ltd., | Συνθεση λιραγλουτιδης |
PE20211202A1 (es) | 2017-08-24 | 2021-07-05 | Novo Nordisk As | Composiciones de glp-1 y sus usos |
-
2020
- 2020-03-31 MA MA055504A patent/MA55504A/fr unknown
- 2020-03-31 JP JP2021558919A patent/JP2022527812A/ja active Pending
- 2020-03-31 CN CN202080026416.4A patent/CN113677702A/zh active Pending
- 2020-03-31 WO PCT/EP2020/059115 patent/WO2020201280A1/fr unknown
- 2020-03-31 EP EP20716442.7A patent/EP3947451A1/fr active Pending
- 2020-03-31 US US16/836,064 patent/US11208477B2/en active Active
-
2021
- 2021-11-19 US US17/530,974 patent/US20220064283A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220064283A1 (en) | 2022-03-03 |
CN113677702A (zh) | 2021-11-19 |
WO2020201280A1 (fr) | 2020-10-08 |
US20200308274A1 (en) | 2020-10-01 |
EP3947451A1 (fr) | 2022-02-09 |
JP2022527812A (ja) | 2022-06-06 |
US11208477B2 (en) | 2021-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52284A (fr) | Anticorps anti-hla-g et leur utilisation | |
MA44776A (fr) | Anticorps anti-vista humain et leur utilisation | |
MA52285A (fr) | Anticorps multispécifiques et leur utilisation | |
UA42761S (uk) | Футляр для зберігання та заряджання навушників | |
MA44225A (fr) | Sulfonylurées et composés apparentés et leur utilisation | |
MA47311A (fr) | Anticorps anti-tgf-bêta et leur utilisation | |
MA53434A (fr) | Anticorps anti-tigit | |
IL277447A (en) | Cell-adapted exosomes and their uses | |
MA52884A (fr) | Anticorps anti-il-11 | |
MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
IL279458A (en) | Neoantigens and their uses | |
MA50440A (fr) | Imidazopyridinamides substituées et leur utilisation | |
MA41316A (fr) | Gènes de détermination du sexe et leur utilisation en reproduction | |
MA44056A (fr) | Anticorps anti-rispéridone et leur utilisation | |
UA41767S (uk) | Ємність | |
MA52542A (fr) | Thérapie cellulaire adoptive | |
MA44777A (fr) | Anticorps humanisés anti-basigine et leur utilisation | |
MA52366A (fr) | Anticorps anti-tl1a optimisés | |
MA44067A (fr) | Anticorps dirigés contre la quétiapine et utilisation associée | |
IL284561A (en) | Neoantigens of the prostate and their uses | |
MA50038A (fr) | Anticorps anti-pd-l1 de et son utilisation | |
MA52190A (fr) | Anticorps anti-trem-1 et utilisations associées | |
MA49250A (fr) | Nouveaux anticorps anti-cd3 | |
ES2973991T3 (es) | Separador y dispositivo electroquímico |